 PARIS CAMBRIDGE, Mass.--BUSINESS WIRE--Regulatory News: NANOBIOTIX Euronext : NANO NASDAQ: NBTX the Company, a late-clinical stage biotechnology company pioneering nanophysics-based approaches to expand treatment possibilities for patients with cancer, today announced the publication of preclinical findings with the University of Texas MD Anderson Cancer Center MD Anderson in the International Journal of Radiation Oncology, Biology, Physics Red Journal. These data support the 